Theriva Biologics, Inc.

TOVX NYSE SEC CIK 894158
Follow Theriva Biologics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$1.5M +66.3% vs same quarter last year
EPS, diluted −$0.03 +93.3% vs same quarter last year
Operating cash flow −$2.9M +33.8% vs same quarter last year
Revenue by quarter
$300K
$0
$0
Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$23.7M
FY24−$25.7M
FY23−$18.3M
FY22−$19.7M
FY21−$14.3M
FY20−$10M
FY19−$15.3M
FY18−$13.4M
FY17−$15.2M
FY16−$27.3M
FY15−$43.7M
FY14−$19.8M
FY13−$12.3M
FY12−$17.1M
FY11−$8.1M
Free cash flowOperating cash flow minus capital expenditure
−$40M−$30M−$20M−$10M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$16.7M
FY24−$16.9M
FY23−$19.2M
FY22−$19.2M
FY21−$12.9M
FY20−$12.2M
FY19−$13.9M
FY18−$17.3M
FY17−$20.4M
FY16−$28.5M
FY15−$39.4M
FY14−$16.1M
FY13−$7.8M
FY12−$8.9M
FY11−$2.9M